These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1738 related articles for article (PubMed ID: 11687110)

  • 1. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin.
    Algra A; de Schryver EL; van Gijn J; Kappelle LJ; Koudstaal PJ
    Cochrane Database Syst Rev; 2001; (4):CD001342. PubMed ID: 11687110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin.
    Algra A; De Schryver EL; van Gijn J; Kappelle LJ; Koudstaal PJ
    Cochrane Database Syst Rev; 2006 Jul; (3):CD001342. PubMed ID: 16855967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
    De Schryver EL; Algra A; van Gijn J
    Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin.
    De Schryver EL; Algra A; Kappelle LJ; van Gijn J; Koudstaal PJ
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD001342. PubMed ID: 22972051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack.
    Sandercock P; Mielke O; Liu M; Counsell C
    Cochrane Database Syst Rev; 2003; (1):CD000248. PubMed ID: 12535394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial.
    ; Halkes PH; van Gijn J; Kappelle LJ; Koudstaal PJ; Algra A
    Lancet Neurol; 2007 Feb; 6(2):115-24. PubMed ID: 17239798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack.
    Saxena R; Koudstaal P
    Cochrane Database Syst Rev; 2004 Oct; (4):CD000187. PubMed ID: 15494992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
    De Schryver EL; Algra A; van Gijn J
    Cochrane Database Syst Rev; 2007 Jul; (3):CD001820. PubMed ID: 17636684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
    De Schryver EL; Algra A; van Gijn J
    Cochrane Database Syst Rev; 2006 Apr; (2):CD001820. PubMed ID: 16625549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
    Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack.
    Naqvi IA; Kamal AK; Rehman H
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD009716. PubMed ID: 32813275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks.
    Aguilar MI; Hart R; Pearce LA
    Cochrane Database Syst Rev; 2007 Jul; (3):CD006186. PubMed ID: 17636831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack.
    Sandercock PA; Gibson LM; Liu M
    Cochrane Database Syst Rev; 2009 Apr; 2009(2):CD000248. PubMed ID: 19370555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic treatment after stroke due to intracerebral haemorrhage.
    Cochrane A; Chen C; Stephen J; Rønning OM; Anderson CS; Hankey GJ; Al-Shahi Salman R
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012144. PubMed ID: 36700520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulants versus antiplatelet agents for acute ischaemic stroke.
    Berge E; Sandercock P
    Cochrane Database Syst Rev; 2002; (4):CD003242. PubMed ID: 12519590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
    Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012169. PubMed ID: 28968483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm.
    Shantsila E; Lip GY
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD003333. PubMed ID: 27629776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks.
    Koudstaal PJ
    Cochrane Database Syst Rev; 2000; (2):CD000187. PubMed ID: 10796315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulants for preventing recurrence following ischaemic stroke or transient ischaemic attack.
    Liu M; Counsell C; Sandercock P
    Cochrane Database Syst Rev; 2000; (2):CD000248. PubMed ID: 10796334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [No role for oral anticoagulants (target INR: 2.0-3.0) after transient ischaemic attack or cerebral infarction of arterial origin; the 'European/Australasian stroke prevention in reversible ischaemia trial' (ESPRIT)].
    De Schryver EL; Halkes PH
    Ned Tijdschr Geneeskd; 2008 Feb; 152(8):445-53. PubMed ID: 18361194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 87.